載入中
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
收盤時
US$1.32
−US$0.075 · -5.38%
盤後
US$1.35
+US$0.03 · +2.27%
10月12日 下午7:02 ET
盤中時間採用ET。市場資料可能有所延遲。
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
日內區間
目前US$1.32
52週區間
目前US$1.32
盤中時間採用ET。市場資料可能有所延遲。
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
日內區間
目前US$1.32
52週區間
目前US$1.32
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 448.58萬 USD | −1069.72萬 USD | 8802.6萬 USD |
| 銷貨成本 | — | — | — | — | 4643.2萬 USD |
| 毛利 | — | — | 448.58萬 USD | −1069.72萬 USD | 4159.4萬 USD |
| 研究與開發 | 899.29萬 USD | 1.59億 USD | 1.14億 USD | 1.56億 USD | 1.9億 USD |
| 銷售、一般及管理費用 | 448.38萬 USD | 2.16億 USD | 6390.78萬 USD | 2億 USD | 9億 USD |
| 營業費用 | 1347.67萬 USD | 3.75億 USD | 5.16億 USD | 3.55億 USD | 21.13億 USD |
| 利息收入 | 108.81萬 USD | 5464萬 USD | 730.03萬 USD | 495.4萬 USD | 2133.3萬 USD |
| 利息支出 | — | — | 10.19萬 USD | — | — |
| 折舊和攤銷 | 85.6萬 USD | 710.76萬 USD | 768.46萬 USD | 948.1萬 USD | 3162.99萬 USD |
| 營業利益 | −1347.67萬 USD | −3.75億 USD | −5.11億 USD | −3.66億 USD | −20.71億 USD |
| 淨利 | −661.46萬 USD | −1.62億 USD | −14.66億 USD | −9.68億 USD | −23.32億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$8.25
上漲空間 525.00%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB90.7萬0.01%108.2億 USD0.44%US$204.26-1.08%
State Street SPDR Portfolio Emerging Markets ETFSPEM41.18萬0.00%175.23億 USD0.07%US$52.12-0.17%
ALPS Medical Breakthroughs ETFSBIO20.07萬0.10%1.91億 USD0.50%US$53.85-2.16%
State Street SPDR S&P China ETFGXC2.05萬0.00%4.46億 USD0.59%US$85.69-0.96%
ProShares Ultra Nasdaq BiotechnologyBIB6015.240.01%9320.36萬 USD1.19%US$108.79-1.90%iShares Biotechnology ETFIBBState Street SPDR Portfolio Emerging Markets ETFSPEMALPS Medical Breakthroughs ETFSBIOState Street SPDR S&P China ETFGXCProShares Ultra Nasdaq BiotechnologyBIBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
